Cadwalader advised HealthCare Royalty Partners on the deal. HealthCare Royalty Partners closed a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO),...
Cadwalader advised HealthCare Royalty Partners on the deal. HealthCare Royalty Partners closed a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO),...
You must be a Standard 1 Year member to access this content.